目的 研究对免疫复合物型治疗性乙肝疫苗不同应答乙肝患者的乙肝病毒基因型有无差别。方法 收集67例经60 ug HBsAg-HBIG (YIC) 治疗的慢性乙肝患者血清， 用S基因聚合酶链反应-限制性片段长度多态性分析(PCR-RFLP)法对其进行HBV基因分型，并结合患者对YIC治疗的不同应答进行分析。结果67例感染乙肝病毒（HBV）患者中，HBV B基因型22例，C基因型43例，未确定者2例。感染HBV B, C 两种基因型的患者对YIC免疫治疗的病毒学与HBeAg的血清转换应答差异无统计学意义. 结论HBV B或C基因型不影响慢性乙肝患者对YIC的治疗应答。

Objective To study whether there are differences in the responses of chronic hepatitis B patients infected with different hepatitis B virus (HBV) genotypes to HBsAg-HBIG therapeutic vaccine. Method Serum samples from sixty seven chronic hepatitis B patients who completed the full course of immunization with 60?g HBsAg-HBIG (YIC) were assayed for their virus genotypes by PCR-RFLP, in association with their viral and HBeAg sero-conversion responses to YIC treatment. Results Among the 67 patients, 22 were infected with HBV genotype B, and 43 were infected with genotype C, while in 2 patients the genotype of HBV could not be identified. In association with the responses to YIC treatment, no significant therapeutic differences were found between patients who were infected with HBV genotype B or with HBV genotype C. Conclusion Infections with HBV genotypes B or C do not affect the therapeutic responses in chronic hepatitis B patients to YIC.